• Skip to main content
  • Skip to secondary menu
  • Skip to footer

Venture Capital Matters

#VentureCapital: VC meets social media

  • Pitch a Startup
  • Market Reports
  • Technologies
    • Technology Events
  • Domain Names for Startups
  • About
  • Contact

Deep Genomics Raises $40 Million in Series B Financing

January 7, 2020 By 3v.org Leave a Comment

Deep Genomics, the leading artificial intelligence (AI) therapeutics company, announced today the closing of its Series B round with $40 million in new investment. The proceeds from this financing will be used to develop new treatments for rare genetic diseases, and to expand the company’s proprietary AI discovery platform to support the discovery and development of novel therapies for more common disorders.

“For over twenty years, our team at Future Ventures has backed visionary companies seeking to change the world for the better,” said Steve Jurvetson, co-founder of Future Ventures and board member of Tesla and SpaceX. “Deep Genomics has pioneered a better way to systematically discover new therapies with a much higher success rate than traditional pharma methods. My partner Maryanna Saenko and I are excited to be joining them on a journey to modernize drug development by using AI to design and derisk drug development programs up front, instead of relying on trial-and-error experiments that are fraught with time delays and high cost.”

“Therapeutically re-engineering the human genome is the final frontier,” said Brendan Frey, founder and CEO of Deep Genomics. “Doing so requires systems that can predict information pertaining to the genome, and the best technology we have for prediction is AI. We have found that the more we explore the universe of genetic therapies using AI, the more we discover dark regions that can be illuminated only with the development of new technology. This financing will enable us to expand our AI technology in the pursuit of new therapeutic opportunities, to advance our Wilson program into the clinic, and to strategically partner assets emerging from our overflowing preclinical pipeline.”

Deep Genomics uses AI to power every stage of drug development, from identifying therapeutic targets that were previously dismissed as being undruggable, to designing novel therapeutic candidates, to designing animal models. The approach results in remarkable clarity and speed: 70 percent of research projects have led to therapeutic leads, and programs have been taken from target discovery to drug candidate in less than 12 months. The company plans to advance two programs to IND in 2020 and obtain Phase 1/2 data for its Wilson disease candidate in 2021.

“The powerful application of AI at Deep Genomics has created a drug development platform that is rapidly producing high quality drug candidates,” said Dion Madsen, partner at the biotech VC firm Amplitude Ventures. “We are excited to support this leading precision medicine company by investing in their new approach to drug development.”

About Deep Genomics. Deep Genomics is developing a universe of individualized genetic medicines by creating AI systems that are used to accelerate all steps of drug discovery and development, including target discovery, lead optimization, toxicity assessment and innovative trial design. Since its inception in 2015, Deep Genomics has used high throughput assays and advanced robotics systems to generate billions of data points and has built dozens of carefully engineered and validated machine learning systems that support drug development. Deep Genomics is located in the heart of Toronto, the fastest growing tech hub in North America. For more information, visit www.deepgenomics.com

Related

Filed Under: PR Tagged With: artificial intelligence (AI) therapeutics, Deep Genomics

Reader Interactions

Leave a Reply Cancel reply

Your email address will not be published. Required fields are marked *

Footer

RSS Market Research Media

  • America’s 100 largest housing markets are overpriced
  • How do media companies perform in digital transformations?
  • A six-step forecasting methodology
  • New skills will be required for the future world of work
  • Two biggest barriers to wider adoption of XR are user experience and limited content
  • The current market value for AR/VR/MR is around $30.7B, and the worldwide market may rise to $300B by 2024
  • Global asset classes compared by market cap in 2021
  • Russian oil production succumbing to the impact of Western sanctions
  • Russia’s default on its foreign debt is around the corner
  • BRIC Investment Funds Have Taken a Beating This Year

RSS Market Analysis

  • Another pandemic may be on the horizon: antimicrobial resistance
  • Low-carbon fuels will be essential for decarbonization
  • Blue hydrogen becoming increasingly cost competitive
  • The construction industry is responsible for 11% of the world’s man-made carbon emissions
  • Military Applications of Quantum Technology
  • New Technologies to Disrupt Traditional Renewable Fuels
  • Australia approves a drought-tolerant genetically modified strain of wheat for use in food
  • The Pentagon’s FY2023 budget request for hypersonic-related research is $4.7 billion
  • Middle East and North Africa region’s economies grew by 5.8% in 2021
  • Job openings hit a record high March

RSS Technologies

  • Cloudflare Unveils New SQL Database Offering
  • Cloudflare announces Workers for Platforms
  • Intel is rolling out new processors designed for data centers
  • EU moves to wean itself off Russian fossil fuels
  • A New Hydrogen-Powered Behemoth
  • BAE Systems to Bring Next-Generation Electric Drive System to Heavy-Duty Industrial Vehicle Market
  • MEMS Speakers Are Replacing Balanced Armature Speakers
  • Trends in data and analytics
  • Apple takes another step towards EV development
  • French company captures methane leaking from abandoned mines

Copyright © 2018 3V.org

Technologies, Market Analysis & Market Research Reports

We use cookies on our website to give you the most relevant experience by remembering your preferences and repeat visits. By clicking “Accept”, you consent to the use of ALL the cookies.
Do not sell my personal information.
Cookie SettingsAccept
Manage consent

Privacy Overview

This website uses cookies to improve your experience while you navigate through the website. Out of these, the cookies that are categorized as necessary are stored on your browser as they are essential for the working of basic functionalities of the website. We also use third-party cookies that help us analyze and understand how you use this website. These cookies will be stored in your browser only with your consent. You also have the option to opt-out of these cookies. But opting out of some of these cookies may affect your browsing experience.
Necessary
Always Enabled
Necessary cookies are absolutely essential for the website to function properly. These cookies ensure basic functionalities and security features of the website, anonymously.
CookieDurationDescription
cookielawinfo-checkbox-analytics11 monthsThis cookie is set by GDPR Cookie Consent plugin. The cookie is used to store the user consent for the cookies in the category "Analytics".
cookielawinfo-checkbox-functional11 monthsThe cookie is set by GDPR cookie consent to record the user consent for the cookies in the category "Functional".
cookielawinfo-checkbox-necessary11 monthsThis cookie is set by GDPR Cookie Consent plugin. The cookies is used to store the user consent for the cookies in the category "Necessary".
cookielawinfo-checkbox-others11 monthsThis cookie is set by GDPR Cookie Consent plugin. The cookie is used to store the user consent for the cookies in the category "Other.
cookielawinfo-checkbox-performance11 monthsThis cookie is set by GDPR Cookie Consent plugin. The cookie is used to store the user consent for the cookies in the category "Performance".
viewed_cookie_policy11 monthsThe cookie is set by the GDPR Cookie Consent plugin and is used to store whether or not user has consented to the use of cookies. It does not store any personal data.
Functional
Functional cookies help to perform certain functionalities like sharing the content of the website on social media platforms, collect feedbacks, and other third-party features.
Performance
Performance cookies are used to understand and analyze the key performance indexes of the website which helps in delivering a better user experience for the visitors.
Analytics
Analytical cookies are used to understand how visitors interact with the website. These cookies help provide information on metrics the number of visitors, bounce rate, traffic source, etc.
Advertisement
Advertisement cookies are used to provide visitors with relevant ads and marketing campaigns. These cookies track visitors across websites and collect information to provide customized ads.
Others
Other uncategorized cookies are those that are being analyzed and have not been classified into a category as yet.
SAVE & ACCEPT